Metabolic & Weight Loss · Source-reviewed dossier
Adipotide
Source-Reviewed Research Dossier
Adipotide is a chimeric peptidomimetic designed to target prohibitin-associated blood vessels in white adipose tissue and deliver a pro-apoptotic sequence. The best-known published study was conducted in obese rhesus monkeys, not in a controlled human trial.
Compound overview
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
- Product type
- Peptide research compound
- Catalog family
- Adipotide
- Research category
- Metabolic & Weight Loss
- Catalog CAS RN
- 859216-15-2
- Catalog sequence
- Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys-Gly-Gly-D(Lys-Leu-Ala-Lys-Leu-Ala-Lys)2
- Evidence status
- Non-human primate and preclinical evidence; no approved human use
- Intended use
- Research, development and manufacturing use only
Literature reference parameters
- Compound or material class
- Prohibitin-targeting peptidomimeticCatalog-family identity
- Evidence scope
- Non-human primate and preclinical evidence; no approved human useDo not generalize beyond the cited model
- Source review
- Primary or authoritative records linked belowChecked 2026-09-01
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
How Adipotide is studied
A target-to-pathway view grounded in the linked research records.
Reported research findings
What published studies report about Adipotide
Reported outcomes are paired with their experimental model and evidence boundary.
Obese-monkey study reported weight and insulin-resistance changes
The published study reported loss of white adipose tissue, body-weight reduction and improved insulin-resistance measures in obese rhesus monkeys.
This was a small non-human-primate experiment with a defined research construct; it was not a human treatment trial.
Read the primary studyTargeted therapeutic formats were compared in obesity models
A later preclinical study compared nanoparticle-targeted therapeutics and peptide bioconjugates as adipose-vascular targeting approaches.
The experiment informs delivery strategy rather than human effectiveness or catalog-lot quality.
Read the primary studyCatalog options
Variant specifications
Pack-level catalog data; lot-level controls remain document-specific.
Specification & documents for AP2
Product specification
Single-component peptide · 2 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Lot documentation
Request by lot: CoA, HPLC purity and MS identity
Specification & documents for AP5
Product specification
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Lot documentation
Request by lot: CoA, HPLC purity and MS identity
Specification & documents for AP10
Product specification
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Lot documentation
Request by lot: CoA, HPLC purity and MS identity
Quality documentation
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Interpret the documents, not just the headline number.
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Research context
Published studies and regulatory records, not customer testimonials or usage guidance.
Obese-monkey study reported weight and insulin-resistance changes
This was a small non-human-primate experiment with a defined research construct; it was not a human treatment trial.
View primary recordTargeted therapeutic formats were compared in obesity models
The experiment informs delivery strategy rather than human effectiveness or catalog-lot quality.
View primary recordCurated references
Third-party publications selected for direct relevance.
-
01
Non-human primate
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys
Barnhart KF, et al. Science Translational Medicine. 2011. PMID 22072637.
-
02
Preclinical comparison
Comparative study of nanoparticle-targeted therapeutics and bioconjugates
Daquinag AC, et al. Molecular Pharmaceutics. 2013. PMID 23871959.
Adipotide questions
Concise answers for researchers comparing identity, evidence and catalog variants.
What is Adipotide?
Adipotide is a chimeric peptidomimetic designed to target prohibitin-associated blood vessels in white adipose tissue and deliver a pro-apoptotic sequence. The best-known published study was conducted in obese rhesus monkeys, not in a controlled human trial.
What evidence is available for Adipotide?
One directly relevant non-human-primate study and additional preclinical delivery research are available.
Does the cited research validate this catalog material?
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
Which quality documents can be requested?
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
How should Adipotide be stored?
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge tools
Continue with structured evidence
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Ready to request a quote?
Selected: AP10 · 10 mg × 10 vials